Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Phase III For Constipation-Predominant IBS To Begin In Late 2001

Executive Summary

Forest will start Phase III trials for dexgloxiglumide in constipation-predominant irritable bowel syndrome before year-end.

You may also be interested in...



Forest Expects Memantine NDA In June; Readies For Benicar Sampling

Forest expects to submit an NDA for the Alzheimer's drug memantine in June, the company told analysts at the Deutsche Bank healthcare conference in Baltimore May 7

Forest Expects Memantine NDA In June; Readies For Benicar Sampling

Forest expects to submit an NDA for the Alzheimer's drug memantine in June, the company told analysts at the Deutsche Bank healthcare conference in Baltimore May 7

Forest Alzheimer's drug development

Forest will submit NDA for memantine "around the end of 2001," but the company appears to view approval based on the two completed pivotal trials to be a long shot. FDA has agreed that the U.S. trial of memantine appears to support efficacy of the drug, but the agency "indicated that a second study performed in Europe would likely need to be reviewed by an advisory committee to determine whether the specific endpoints utilized were adequate to qualify it as a second study demonstrating efficacy," Forest said. The company is initiating additional Phase III studies in both mild-to-moderate and moderate-to-severe Alzheimer's in case additional evidence of efficacy is required. Forest hopes to launch the product "by the second half of 2003"; a decision by the advisory committee that the European study is sufficient would allow for an earlier launch

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel